aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
From TechCrunch
By Paul Sawers
April 24, 2024
Conversational AI platform Parloa has nabbed $66 million in a Series B round, a year after it raised $21 million from a swathe of European investors to propel its international growth.
The German company is focusing on the U.S. in particular, and last year opened an office in New York, too. It says this hub helped it sign up “several Fortune 200 companies” in the region. For the latest round, Parloa has secured Altimeter Capital as lead backer, a U.S.-based VC firm notable for its investments in the likes of Uber, Airbnb, Snowflake, Twilio and HubSpot.
AI and automation is not new in customer service, but with a new wave of large language models (LLMs) and generative AI infrastructure, truly smart “conversational” AI (i.e., not dumb chatbots) is again firmly in investors’ focus. Established players continue to raise substantial sums — Kore.ai, for example, closed a chunky $150 million round a few months ago from big-name backers such as Nvidia. Elsewhere, entrepreneur and former Salesforce CEO, Bret Taylor, in February launched a new customer experience platform called Sierra that’s built around the concept of “AI agents,” and has raised more than $100 million from venture investors.
Parloa is well-positioned to capitalize on the “AI with everything” hype that has hit fever pitch these past couple of years as companies seek new ways to improve efficiency through automation.
Founded in 2018, the startup has already secured high-profile customers such as European insurance giant, Swiss Life, and sporting goods retailer, Decathlon, both of which use Parloa’s platform to automate customer communications, including emails and instant messaging.
However, “voice” is where co-founder and CEO Malte Kosub reckons Parloa stands out.
“Our strategy has always been centered around ‘voice first,’ the most critical and impactful facet of the customer experience,” Kosub told TechCrunch over email. “As a result, Parloa’s AI-based voice conversations sound more human than any other solution.”
Co-founder and CTO, Stefan Ostwald, says that AI has been a core part of Parloa’s DNA since its inception six years ago. The company uses a mix of proprietary and open source LLMs to train models for speech-to-text use cases.
“We’ve trained a variety of speech-to-text models on phone audio quality and customer service use cases. We’ve developed a custom telephony infrastructure to minimize latency — a key challenge in voice automation — as well as a proprietary LLM agent framework for customer service,” he said.
Parloa had previously raised around $25 million, the bulk of which arrived via its Series A round last year. Now with another $66 million in the bank, it’s well-financed to double down on both its European and U.S. growth. Kosub noted that the company has tripled its revenue in each of the past three years.
“We successfully entered the U.S. market in 2023. We’ve always had confidence in the excellence and competitiveness of our product, but the overwhelming and rapid success it achieved in the U.S. surpassed everyone’s expectations,” Kosub said.
Aside form lead investor Altimeter, Parloa’s Series B saw checks from EQT Ventures, Newion, Senovo, Mosaic Ventures and La Familia Growth. Today’s funding brings the company’s total capital raised to $98 million, following its $21 million Series A, which was led by EQT Ventures, in 2023.
Share:
Retro Biosciences, backed by Sam Altman, is raising $1 billion to extend human lifespan
OpenAI CEO Sam Altman is doubling down on Retro Biosciences, a biotech startup based in San Francisco that wants humans to live 10 years longer than what it calls a healthy human lifespan. Altman previously provided Retro Biosciences’ entire seed round of $180 million. Now, the startup is raising a $1 billion Series A that Altman is joining, The Financial Times reports. Retro Biosciences, which says it plans to launch trials for drugs targeting diseases like Alzheimer’s, recently trained a mode
Jan 24, 2025
TechCrunch Disrupt 2025 tickets now on sale: Lowest rates ever
We’re kicking things off earlier than ever! TechCrunch Disrupt 2025 tickets are officially on sale. Don’t miss your chance to snag them at the lowest rates of the year! Immerse yourself in the epicenter of tech innovation at Disrupt 2025! From October 27 to 29, Moscone West in San Francisco transforms into the global hub for technology and venture capital. Experience 250+ powerful sessions, 200+ expert-led discussions, the thrilling Startup Battlefield 200, and unparalleled networking with 10,0
Jan 24, 2025
Neko Health’s unicorn-sized Series B is larger than some Series C rounds
Welcome to Startups Weekly — your weekly recap of everything you can’t miss from the world of startups. Want it in your inbox every Friday? Sign up here. This week was supposed to be a short one in the U.S., as it started with a holiday. But Inauguration Day kept some founders busy, and the following days brought us more than their fair share of startup news. Most interesting startup stories from the week Image Credits:David Paul Morris/Bloomberg via Getty This week reminded us that not all sal
Jan 24, 2025
Don't miss our latest news and updates. Subscribe to the newsletter